INT145957

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.43
First Reported 2007
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 5
Total Number 5
Disease Relevance 2.12
Pain Relevance 0.61

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (GLP1R) plasma membrane (GLP1R) signal transducer activity (GLP1R)
Anatomy Link Frequency
blood 2
Plasma 2
GLP1R (Homo sapiens)
Pain Link Frequency Relevance Heat
substance P 2 100.00 Very High Very High Very High
bradykinin 2 100.00 Very High Very High Very High
Enkephalin 1 100.00 Very High Very High Very High
Neuropeptide 4 93.52 High High
agonist 24 93.12 High High
adenocard 4 84.44 Quite High
tolerance 7 84.32 Quite High
potassium channel 2 32.48 Quite Low
headache 6 5.00 Very Low Very Low Very Low
Central nervous system 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Natriuresis 2 100.00 Very High Very High Very High
Diabetes Mellitus 188 99.80 Very High Very High Very High
Obesity 13 96.08 Very High Very High Very High
Sprains And Strains 1 91.84 High High
Hypoglycemia 34 91.28 High High
Impaired Glucose Tolerance 7 84.96 Quite High
Myocardial Infarction 4 66.52 Quite High
Coronary Artery Disease 1 63.28 Quite High
Weight Loss 11 54.36 Quite High
Hyperglycemia 11 46.48 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Plasma concentrations of both incretins increase within 5 to 15 min after meal ingestion: GLP-1 is primarily released by the ingestion of carbohydrate, fat and protein, whereas GIP is mainly liberated by the ingestion of carbohydrate and fat (Deacon 2005).
Positive_regulation (increase) of Localization (released) of GLP-1 in Plasma
1) Confidence 0.43 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597770 Disease Relevance 0.32 Pain Relevance 0.09
In order to utilise GLP-1 action for type 2 diabetes therapy, two options are presently available [6]:
Positive_regulation (utilise) of Localization (action) of GLP-1 associated with diabetes mellitus
2) Confidence 0.42 Published 2010 Journal Pediatr Nephrol Section Body Doc Link PMC2874027 Disease Relevance 0.61 Pain Relevance 0.17
Neutral endopeptidase (NEP) is the major enzyme involved in the metabolic inactivation of a number of bioactive peptides including the enkephalins, substance P, endothelin, bradykinin and atrial natriuretic factor, as well as the incretin hormone glucagon-like peptide 1 (GLP-1), which is a potent stimulator of insulin secretion.
Positive_regulation (inactivation) of Localization (secretion) of GLP-1 associated with natriuresis, enkephalin, bradykinin and substance p
3) Confidence 0.42 Published 2007 Journal Acta Crystallogr. D Biol. Crystallogr. Section Abstract Doc Link 17704566 Disease Relevance 0.26 Pain Relevance 0.20
Specifically, it has been demonstrated that the endogenous human incretin hormone GLP-1 decreases blood glucose by several pathways – via the regulation of insulin and glucagon, inhibition of gastric emptying, and suppression of appetite, and that the normal physiologic response to GLP-1 is impaired in type 2 diabetes.9,10,11 GLP-1 stimulates insulin secretion in a glucose-dependent manner and suppresses glucagon secretion.10 In normal physiology, oral ingestion of nutrients stimulates GIP and GLP-1 secretion, which in turn increases insulin secretion from pancreatic beta-cells.
Positive_regulation (stimulates) of Localization (secretion) of GLP-1 in blood associated with diabetes mellitus
4) Confidence 0.36 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2878957 Disease Relevance 0.64 Pain Relevance 0.11
Administration of metformin to obese subjects was also found to increase levels of active GLP-1 after a glucose load: this phenomenon appears to occur through mechanisms other than DPP-4 inhibition, and may instead be due to direct stimulation of GLP-1 secretion or a reduction in DPP-4 secretion (Mannucci et al 2001; Lenhard et al 2004).
Positive_regulation (stimulation) of Localization (secretion) of GLP-1 associated with obesity
5) Confidence 0.17 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597758 Disease Relevance 0.29 Pain Relevance 0.04

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox